Clinical data | |
---|---|
Trade names | Lutionex |
Other names | Dimegestone; R-2453; RU-2453; 17α-Methyl-δ9-19-norprogesterone; 17α-Methyl-19-norpregna-4,9-diene-3,20-dione |
Routes of administration | By mouth[1] |
Drug class | Progestogen; Progestin |
ATC code | |
Pharmacokinetic data | |
Bioavailability | Good[2] |
Metabolism | Hydroxylation, others[2] |
Metabolites | • 21-Hydroxydemegestone[2] • Others[2] |
Excretion | Urine[2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.030.278 |
Chemical and physical data | |
Formula | C21H28O2 |
Molar mass | 312.453 g·mol−1 |
3D model (JSmol) | |
| |
|
Demegestone, sold under the brand name Lutionex, is a progestin medication which was previously used to treat luteal insufficiency but is now no longer marketed.[3][4][5][6][7] It is taken by mouth.[2][1]
Demegestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[6][2][8] It has no androgenic activity.[2]
Demegestone was first described in 1966 and was introduced for medical use in France in 1974.[3][4] It has only been marketed in France, and has since been discontinued in this country.[5][4]
RaynaudCousty1974
was invoked but never defined (see the help page).pmid3194612
was invoked but never defined (see the help page).